WuXi Biologics (Cayman) Inc. (abbreviated as WuXi Bio) will hold its 2026 annual general meeting (AGM) on 10 June 2026 at 10:00 a.m. at the Sheraton Shanghai Waigaoqiao Hotel, Shanghai Free Trade Zone.

Key agenda items include:

1. Financial Statements: Shareholders will vote on the acceptance of the audited consolidated financial statements and accompanying directors’ and independent auditor’s reports for the year ended 31 December 2025.

2. Board Composition: Three directors are up for individual re-election—Non-executive Director Dr. Ge Li and Independent Non-executive Directors Mr. Kenneth Walton Hitchner III and Dr. Jue Chen.

3. Remuneration: The board, or a duly authorized committee, will be empowered to set directors’ remuneration for the 2026 financial year.

4. Auditor: Re-appointment of Deloitte Touche Tohmatsu as external auditor and authorization for the board or its committee to determine audit fees will be decided.

5. Share Issuance Authority: A general mandate will be sought allowing directors to issue, allot and deal with company shares, including any sale or transfer of treasury shares.

6. Share Repurchase Mandate: A separate mandate will authorize the board to repurchase the company’s own shares.

Shareholders on record may appoint a proxy—an individual need not be a shareholder—to attend and vote on their behalf. Completed proxy forms must reach Tricor Investor Services Limited, WuXi Bio’s Hong Kong branch share registrar, by 10:00 a.m. on 8 June 2026. Attendance in person at the AGM will override any prior proxy submission.